← Back to Compliance
GxP Requirements for New Approach Methodologies
GxP encompasses the quality guidelines and regulations governing pharmaceutical and biotech industries. For NAMs, implementing appropriate GxP standards is essential for regulatory acceptance. This guide covers GLP, GMP, GCP requirements and how they apply to organ-on-chip, organoid, and other NAMs technologies.
What is GxP? The "x" represents the specific area: GLP (Laboratory Practice), GMP (Manufacturing Practice), GCP (Clinical Practice). Each ensures quality, safety, and data integrity in their respective domains.
GLP: Good Laboratory Practice
GLP is the cornerstone GxP standard for NAMs development and validation, ensuring quality and integrity of nonclinical safety studies submitted to regulatory agencies[1].
Core GLP Requirements for NAMs
- Study Director - Qualified individual responsible for overall study conduct and final report
- Quality Assurance Unit - Independent review of protocols, procedures, and data
- Standard Operating Procedures - Documented procedures for NAMs operation, maintenance, data collection
- Test System Characterization - Cell source documentation, passage limits, differentiation protocols
- Equipment Qualification - IQ/OQ/PQ for microfluidic systems, incubators, analytical instruments
- Data Integrity - ALCOA+ principles (Attributable, Legible, Contemporaneous, Original, Accurate)
NAMs-Specific GLP Adaptations
| Traditional Element | NAMs Adaptation |
|---|
| Test System (animals) | Cell type, source, passage, differentiation state |
| Animal Housing | Incubator conditions, media composition, flow rates |
| Clinical Observations | Morphology, biomarkers, barrier integrity, functional endpoints |
| Necropsy | Chip disassembly, cell harvest, downstream analysis protocols |
GMP: Good Manufacturing Practice
GMP applies when NAMs platforms are commercially manufactured or when NAMs produce therapeutic products.
GMP Applications in NAMs
- Device Manufacturing - Commercial organ-on-chip platforms require GMP compliance
- Cell Banking - Master and working cell banks for NAMs require GMP facilities
- Therapeutic Production - Using NAMs to manufacture cell therapies or biologics
- Reagent Production - Culture media and specialized matrices for regulated applications
GCP: Good Clinical Practice
While NAMs are primarily nonclinical, GCP intersects when patient-derived materials are used or NAMs inform clinical decisions.
- Patient-Derived Organoids - Informed consent for tissue use in NAMs
- Personalized Medicine - NAMs guiding individual treatment selection
- Companion Diagnostics - NAMs-based tests used alongside therapeutics
Key Point: Early engagement with regulatory agencies helps clarify GxP expectations for specific NAMs applications. FDA, EMA, and PMDA all offer pre-submission meeting opportunities.
Implementation Checklist
- Establish Quality Management System (QMS)
- Develop and validate SOPs for all critical procedures
- Qualify equipment and facilities
- Train personnel with documented evidence
- Implement document control and change management
- Establish deviation and CAPA procedures
- Conduct internal audits and management reviews
© 2025 Patient Analog. All rights reserved.
Educational content created by J Radler for the biotech and scientific community. Last updated: February 4, 2026.
Free to share for educational purposes with attribution.